Assembly Biosciences ASMB
NASDAQ ASMB
$20.46 -0.73 (-3.45%)
At close: Oct 21, 2026 · 4:00 PM EDT

Assembly Biosciences (ASMB) Short term Debt (2010)

Updated

Assembly Biosciences (ASMB) reported Short term Debt of $419,380 for Q4 2010.

Analysis

Assembly Biosciences (ASMB) Short term Debt (2010) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn
10 Assembly Biosciences 386.12 Mn -641.50 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2010 419,380.00
API Access

Assembly Biosciences Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=ASMB&period=max&api_key=YOUR_API_KEY